Steigerwald Gordon & Koch Inc. Reduces Stock Position in Danaher Co. (NYSE:DHR)

Steigerwald Gordon & Koch Inc. trimmed its position in Danaher Co. (NYSE:DHR) by 1.8% during the fourth quarter, Holdings Channel.com reports. The firm owned 16,360 shares of the conglomerate’s stock after selling 292 shares during the period. Steigerwald Gordon & Koch Inc.’s holdings in Danaher were worth $3,756,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the company. Decker Retirement Planning Inc. purchased a new position in shares of Danaher during the 4th quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher in the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new position in Danaher during the 3rd quarter worth approximately $40,000. FSA Wealth Management LLC purchased a new position in shares of Danaher in the third quarter valued at $50,000. Finally, Darwin Wealth Management LLC acquired a new stake in shares of Danaher during the third quarter valued at about $55,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Trading Down 1.4 %

Shares of NYSE DHR opened at $238.41 on Friday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. Danaher Co. has a 52 week low of $222.53 and a 52 week high of $281.70. The business has a 50 day simple moving average of $234.85 and a 200 day simple moving average of $253.32. The stock has a market cap of $172.20 billion, a price-to-earnings ratio of 45.50, a PEG ratio of 4.23 and a beta of 0.83.

Danaher (NYSE:DHR) last released its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, topping analysts’ consensus estimates of $1.57 by $0.14. The firm had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue was up 3.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.02 EPS. On average, research analysts predict that Danaher Co. will post 7.49 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date is Friday, December 27th. Danaher’s dividend payout ratio is presently 20.61%.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DHR. Scotiabank started coverage on shares of Danaher in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 target price on the stock. Guggenheim initiated coverage on shares of Danaher in a research note on Thursday, December 19th. They set a “buy” rating and a $275.00 price objective on the stock. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 target price on the stock in a report on Thursday, October 31st. TD Cowen increased their price target on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Finally, Stephens reaffirmed an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a research note on Wednesday, October 23rd. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $286.80.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.